Author

A. Mulder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

F. H. J. Claas· 3 shared A. A. de Waard· 2 shared M. L. M. Jongsma· 2 shared R. M. Spaapen· 2 shared S. Bliss· 2 shared T. Verkerk· 2 shared A. D. Hollander· 1 shared A. H. de Ru· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. H. J. Claas

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The appearance of sugI mixed loci in three individuals during treatment for MDR-TB, supports the involvement of sugI in Mycobacterium tuberculosis d-cycloserine resistance in vivo.

R. M. Anthony, M. Molemans, O. Akkwerman, M. G. G. Sturkenboom, A. Mulder, R. de Zwaan, D. van Soolingen, J.-W. Alffenaar, F. C. M. van Leth, S. Ghimire, N. Yastskevich, A. Skrahina, N. Ciobanu, N. Turcan, V. Crudu

This study identifies mixed SNPs in the sugI gene from M. tuberculosis isolates during MDR-TB treatment, suggesting a potential role of sugI in d-cycloserine resistance.

bioRxiv · May 30, 2023 · PreprintMicrobiology

Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance

Y. D. Muller, L. M. R. Ferreira, E. Ronin, P. Ho, V. Nguyen, G. Faleo, Y. Zhou, K. Lee, K. K. Leung, N. Skartsis, A. M. Kaul, A. Mulder, F. H. J. Claas, J. A. Wells, J. A. Bluestone, Q. Tang

This paper develops an anti-HLA-A2 CAR for Tregs to induce transplant tolerance, showing they target HLA-A2-expressing grafts and suppress immune rejection.

bioRxiv · Aug 16, 2021Immunology

The SPPL3-defined glycosphingolipid repertoire regulates immune responses by improving HLA class I access

M. L. M. Jongsma, M. Raaben, A. A. de Waard, T. Zhang, B. Cabukusta, R. Platzer, V. A. Blomen, A. Xagara, T. Verkerk, S. Bliss, L. Janssen, E. Stickel, S. Holst, R. Plomp, A. Mulder, , R. M. Spaapen

The paper identifies a glycosphingolipid (GSL) signature that inhibits HLA-I antigen presentation and shows its reversal by clinically approved drugs.

bioRxiv · Sep 26, 2020Immunology

ERAP2 increases the abundance of a peptide submotif highly selective for the Birdshot Uveitis-associated HLA-A29

W. Venema, S. Hiddingh, J. H. de Boer, F. Claas, A. Mulder, A. D. Hollander, E. Stratikos, S. Sarkizova, L. v. d. Veken, G. Janssen, P. v. Veelen, J. J. Kuiper

The paper investigates how ERAP2 affects HLA-A29 peptide presentation in BU and identifies an HLA-A29-specific peptide motif linked to autoantigens.

bioRxiv · Aug 14, 2020 · PreprintImmunology

PAKC: A novel Panel of HLA class I Antigen presentation machinery Knockout Cells from the same genetic origin

A. A. de Waard, T. Verkerk, M. L. M. Jongsma, K. Hoefakker, S. Sethumadhavan, C. Gerke, S. Bliss, G. M. C. Janssen, A. H. de Ru, F. H. J. Claas, A. Mulder, R. Tampe, P. A. van Veelen, A. Halenius, R. M. Spaapen

The paper generates a panel of APM knockout cell lines to study HLA class I antigen presentation and its role in immune responses.

bioRxiv · Jan 24, 2020Immunology